Preclinically, PARP inhibition elicits a potent anti-tumour immune response through activation of the STING pathway in both BRCA1-deficient tumour cells and dendritic cells, possibly indicating an association between innate and systemic immunity [18, 19]. Here, BRCA1 is linked to neoplasm.